10-Q: MDB Capital Holdings Reports Wider Q2 Loss, Control Issues

MDB Capital Holdings, LLC reported a significantly increased net loss for the second quarter and first half of 2025, driven by unrealized investment losses and a new equity loss from its deconsolidated eXoZymes subsidiary, alongside identified material weaknesses in internal controls.

Summary

• Net loss attributable to MDB Capital Holdings, LLC for the six months ended June 30, 2025, increased to $14,834,993, compared to $11,489,866 for the same period in 2024.
• Total operating income swung to a loss of $1,072,322 for the six months ended June 30, 2025, from an income of $1,628,061 in the prior year period.
• Unrealized losses on investment securities, net, totaled $3,655,812 for the six months ended June 30, 2025, a significant decline from a $152,276 gain in the comparable 2024 period.
• Fee income increased by 64.2% to $2,140,238 for the six months ended June 30, 2025, up from $1,303,398 in 2024.
• Other operating income rose by 157.1% to $443,252 for the six months ended June 30, 2025, compared to $172,387 in 2024.
• Total operating costs decreased by 16.8% to $12,230,267 for the six months ended June 30, 2025, from $14,699,970 in 2024, primarily due to the deconsolidation of eXoZymes and reduced compensation expenses.
• Equity in loss of equity method investee, eXoZymes, contributed a loss of $1,979,744 for the six months ended June 30, 2025, following its deconsolidation in November 2024.
• Cash and cash equivalents decreased to $17,091,584 at June 30, 2025, from $20,437,492 at December 31, 2024.
• Total assets decreased to $63,517,689 at June 30, 2025, from $71,976,399 at December 31, 2024.
• Working capital decreased to $17,739,227 at June 30, 2025, from $24,928,197 at June 30, 2024.
• Net cash used in operating activities improved to $3,406,093 for the six months ended June 30, 2025, from $6,468,895 in the prior year period.
• Disclosure controls and procedures were deemed not effective as of June 30, 2025, due to material weaknesses in internal control over financial reporting, with remediation efforts ongoing.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significantly increased net loss, substantial unrealized investment losses, a new equity loss from a deconsolidated subsidiary, and the disclosure of ineffective internal controls. While some operating cash burn decreased and fee income increased, the overall financial deterioration and governance issues outweigh these positives.

Positives

• Fee income increased by 64.2% to $2,140,238 for the six months ended June 30, 2025, indicating stronger investment banking and brokerage activity.
• Other operating income grew by 157.1% to $443,252 for the six months ended June 30, 2025, reflecting increased activity in legal and strategy services and clearing operations.
• Total operating costs decreased by 16.8% for the six months ended June 30, 2025, primarily due to the deconsolidation of eXoZymes and reduced compensation expenses.
• Net cash used in operating activities significantly decreased to $3,406,093 for the six months ended June 30, 2025, from $6,468,895 in the prior year, indicating improved operational cash management.
• Public Ventures' net capital of $8,612,745 at June 30, 2025, substantially exceeded the minimum SEC requirement of $250,000 and the DTC membership requirement of $5,000,000.

Negatives

• Net loss attributable to MDB Capital Holdings, LLC widened by 29.1% to $14,834,993 for the six months ended June 30, 2025, compared to $11,489,866 in the prior year.
• Total operating income swung from a gain of $1,628,061 in the first half of 2024 to a loss of $1,072,322 in the first half of 2025.
• Unrealized losses on investment securities, net, were $3,655,812 for the six months ended June 30, 2025, a significant negative swing from a $152,276 gain in the comparable 2024 period.
• Equity in loss of equity method investee, eXoZymes, resulted in a new loss of $1,979,744 for the six months ended June 30, 2025, following its deconsolidation.
• Cash and cash equivalents decreased by 16.4% to $17,091,584 at June 30, 2025, from $20,437,492 at December 31, 2024.
• Total assets decreased by 11.8% to $63,517,689 at June 30, 2025, from $71,976,399 at December 31, 2024.
• Working capital decreased by $7,188,970 to $17,739,227 at June 30, 2025, from $24,928,197 at June 30, 2024, primarily due to funding operations.
• Interest income decreased by 46.0% to $355,943 for the six months ended June 30, 2025, due to lower cash balances.

Risks

• Disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in internal control over financial reporting, which could adversely affect the ability to record, process, summarize, and report financial information accurately.
• Partner companies' endeavors to create and bring new technologies to market may not come to fruition or reach commercial viability, potentially requiring further funding or business discontinuation.
• Technologies developed by partner companies may not gain widespread or timely market acceptance, leading to financial losses.
• Technologies undergoing regulatory scrutiny, testing, and approval may ultimately fail to receive necessary approvals from relevant regulatory bodies.
• Inflation risk could have a material effect on operations, impacting the general economy.
• A potential recession in the United States economy could impact the general business environment and capital markets, affecting the company's financial services segment and asset values.
• Changes to United States tariff and import/export regulations may have an adverse effect on business, financial condition, and results of operations, increasing costs and restricting access to suppliers or customers.
• Government actions on tariffs, trade policies, immigration, and research grants/funding may impede the ability to conduct research and raise capital for partner companies and clients.
• The requirement to comply with the Uniform Net Capital Rule 15c3-1 may limit Public Ventures' ability to issue dividends to its parent company.
• Indemnification obligations to the clearing broker for customer losses have no maximum amount, posing an uncapped liability risk.

Future Outlook

The company is continuing to monitor macroeconomic factors such as inflation, potential recession, and changes in U.S. trade policies, which could impact the general business environment and capital markets. There is ongoing remediation of previously identified material weaknesses in internal control over financial reporting, with expected material improvements. Partner companies' technology development and commercial viability remain uncertain, with potential needs for further funding or discontinuation if market acceptance or regulatory approvals are not achieved.

Management Comments

• Management believes that the financial statements for the periods covered by and included in this Quarterly Report on Form 10-Q fairly state, in all material respects, the financial position, results of operations and cash flows for the periods presented in conformity with GAAP, notwithstanding the material weaknesses in internal control over financial reporting.
• Management is implementing measures designed to ensure that control deficiencies contributing to the previously disclosed material weakness are remediated, such that these controls are designed, implemented, and operating effectively, including expansion of controls based on updated enhanced risk assessments and redesigning the financial reporting process.

Industry Context

The company operates in the financial services sector, specifically investment banking and brokerage, and also has a technology development segment. The significant unrealized losses on investment securities reflect broader market volatility or specific portfolio performance. The increased fee income in the broker-dealer segment suggests some resilience or successful deal-making despite overall market conditions. The challenges in technology development, particularly with eXoZymes, highlight the inherent risks and capital intensity of early-stage biotech ventures. The general economic outlook, including inflation and recession risks, is a pervasive concern across industries, potentially impacting capital raising and investment activity.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings, and not aware of any pending or threatened litigation that would have a material adverse effect on business, operating results, cash flows, or financial condition.

Related Party Transactions

• Payments of $928,867 for the six months ended June 30, 2025, to Point 1286 (controlled by principal members) for outsourced services, an increase from $625,246 in the prior year.
• PatentVest recognized revenues of $69,288 from transactions with eXoZymes for the six months ended June 30, 2025.
• A promissory note with an outstanding balance of $252,448 was issued to Paulex as part of acquiring a 30.6% ownership interest on May 15, 2025.
• Related party receivables totaling $54,291 were recorded for services performed by PatentVest on behalf of eXoZymes.
• Accrued expenses of $18,140 were payable to officers and directors for reimbursable expenses.

Stakeholder Impact

• Shareholders: Experienced a significant increase in net loss per share and a decrease in total equity, potentially impacting shareholder value. The ineffectiveness of internal controls also poses a governance concern.
• Employees: Stock-based compensation was modified from RSUs to stock options, potentially altering long-term incentives. Personnel departures occurred in the Broker Dealer segment.
• Customers: Public Ventures' increased fee income and clearing operations activity suggest continued engagement and service provision to customers.
• Creditors: The company maintains a revolving credit facility, but no drawdowns have been made, indicating no immediate increase in debt burden from this facility. However, the promissory note to Paulex represents a new debt obligation.
• Regulatory Bodies: The identified material weaknesses in internal controls and ongoing remediation efforts will be under scrutiny by regulatory authorities like the SEC.

Next Steps

• Continue remediation efforts for material weaknesses in internal control over financial reporting, including expanding controls and redesigning the financial reporting process.
• Monitor macroeconomic trends (inflation, recession, trade policies) and adjust business and financing plans as needed.
• M1 is required to achieve certain development milestones within designated time periods under the License Agreement with Mayo, including payments for Phase II and Phase III clinical trial initiation, and FDA New Drug Application acceptance and approval.

Key Dates

Recommendation

The company reported a significantly wider net loss, primarily driven by substantial unrealized investment losses and a new equity loss from its deconsolidated eXoZymes subsidiary. The disclosure of ineffective internal controls is a serious concern, indicating potential risks to financial reporting reliability. While there are some positive signs, such as increased fee income and reduced cash burn from operations, these are overshadowed by the overall financial deterioration and governance issues. A 'hold' recommendation is appropriate for existing investors who may wish to monitor the effectiveness of the ongoing remediation efforts for internal controls and the performance of the core broker-dealer segment. New investors should exercise extreme caution due to the significant losses and control weaknesses.

Keywords

MDB Capital Holdings, 10-Q, Quarterly Report, Financial Services, Broker-Dealer, Investment Banking, Technology Development, eXoZymes, MDB Minnesota One, SEC Filing, Financial Performance, Net Loss, Operating Income, Investment Securities, Internal Controls, Risk Factors, Capital Resources, Equity Method Investment, Stock-Based Compensation